A5045954244- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- RNA Interference and Gene Delivery
- Phagocytosis and Immune Regulation
- Virus-based gene therapy research
- Immune cells in cancer
- Radiopharmaceutical Chemistry and Applications
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- vaccines and immunoinformatics approaches
- Advanced biosensing and bioanalysis techniques
- Cancer Research and Treatments
- Advanced Biosensing Techniques and Applications
- Trace Elements in Health
- Cytokine Signaling Pathways and Interactions
- Lymphatic System and Diseases
- Angiogenesis and VEGF in Cancer
- Vagus Nerve Stimulation Research
- Ferroptosis and cancer prognosis
- interferon and immune responses
- Protein Degradation and Inhibitors
- Lung Cancer Treatments and Mutations
- Axon Guidance and Neuronal Signaling
Vrije Universiteit Brussel
2015-2024
Bio-Medical Science (South Korea)
2012-2021
Blind and Sight Impaired Society
2021
Université Libre de Bruxelles
2021
Queen Mary University of London
2012
Ghent University
2012
The use of tumor-associated antigen (TAA) mRNA for therapeutic purposes is under active investigation. To be effective, vaccines need to deliver activation stimuli in addition TAAs dendritic cells (DC). In this study, we evaluated whether intranodal delivery TAA together with TriMix, a mix encoding CD40 ligand, constitutive Toll-like receptor 4 and CD70, results the situ modification maturation DCs, hence, priming TAA-specific T cells. We showed selective uptake translation vivo by lymph...
Abstract Modulating the activity of tumor-infiltrating dendritic cells (TiDC) provides opportunities for novel cancer interventions. In this article, we report on our study uptake mRNA by CD8α+ cross-presenting TiDCs upon its intratumoral (i.t.) delivery. We exploited property to deliver encoding costimulatory molecule CD70, activation stimuli CD40 ligand, and constitutively active Toll-like receptor 4, referred as TriMix mRNA. show that are reprogrammed mature antigen-presenting migrate...
Cancer vaccines based on mRNA are extensively studied. The fragile nature of has instigated research into carriers that can protect it from ribonucleases and as such enable its systemic use. However, carrier-mediated delivery been linked to production type I interferon (IFN) was reported compromise the effectiveness vaccines. In this study, we evaluated a cationic lipid for encapsulation mRNA. nanometer-sized, negatively charged particles (LMPs) efficiently transfected dendritic cells...
Immune checkpoint inhibition (ICI) is a promising cancer therapy, which has progressed rapidly from preclinical concept to clinical implementation. Commonly considered targets in ICI are CTLA-4, PD-1/PD-L1, and LAG-3, the list grows. As generally only beneficial for subset of patients, there need select patients that eligible therapy as well monitor response. There growing interest do this noninvasively, by molecular imaging with target-specific tracers. To day, noninvasive focused on CTLA-4...
Recent advances in the field of immune-oncology led to discovery next-generation immune checkpoints (ICPs). Lymphocyte activation gene-3 (LAG-3), being most widely studied among them, is explored as a target for treatment cancer patients. Several antagonistic anti-LAG-3 antibodies are developed and prime candidates clinical application. Furthermore, validated therapies targeting cytotoxic T-lymphocyte–associated protein-4, programmed cell-death protein-1, or ligand-1 showed that only subsets...
Targeted radionuclide therapy (TRT) using targeting moieties labeled with α-particle–emitting radionuclides (α-TRT) is an intensely investigated treatment approach as the short range of α-particles allows effective local lesions and micrometastases. However, profound assessment immunomodulatory effect α-TRT lacking in literature. <b>Methods:</b> Using flow cytometry tumors, splenocyte restimulation, multiplex analysis blood serum, we studied immunologic responses ensuing from TRT antihuman...
Lentiviral vectors (LVs) provide unique opportunities for the development of immunotherapeutic strategies, as they transduce a variety cells in situ, including antigen-presenting (APCs). Engineering LVs to specifically APCs is required promote their translation towards clinic. We report on Nanobody (Nb) display technology target dendritic (DCs) and macrophages. This innovative approach exploits budding mechanism incorporate an APC-specific Nb binding-defective, fusion-competent form VSV.G...
Efficacious antitumor vaccines strongly stimulate cancer-specific effector T cells and counteract the activity of tumor-infiltrating immunosuppressive cells. We hypothesised that combining cytokine expression with silencing programmed cell death ligand 1 (PD-L1) could potentiate anticancer immune responses lentivector vaccines. Thus, we engineered a collection lentivectors simultaneously co-expressed an antigen, PD-L1-silencing shRNA, various cell-polarising cytokines, including interferon γ...
Neuropilin-1 (NRP-1) is a co-receptor for semaphorins and vascular endothelial growth factor (VEGF) family members that can be expressed on cancer cells tumor-infiltrating myeloid, lymphoid cells. It has been linked to tumor-promoting environment upon interaction with semaphorin 3A (Sema3A). Nanobodies (Nbs) targeting NRP-1 were generated their potential hamper the NRP-1/Sema3A impact colorectal carcinoma (CRC) development was evaluated in vivo through generation of anti-NRP-1-producing CRC...
Immune checkpoint blockade (ICB) of the PD-1 pathway revolutionized survival forecast for advanced non-small cell lung cancer (NSCLC). Yet, majority PD-L1
Molecular mimetics of the caspase activator second mitochondria-derived (SMAC) are being investigated for use in cancer therapy, but an understanding vivo effects remains incomplete. In this study, we offer evidence that SMAC elicit a proinflammatory cell death cells engages adaptive antitumor immune response. Cancer different histologic origin underwent apoptosis when transduced with lentiviral vectors encoding cytosolic form mimetic LV-tSMAC. Strikingly, treatment tumor-bearing mice...
Antigen-presenting cells are a heterogeneous group of that characterized by their functional specialization. Consequently, targeting specific antigen-presenting cell subsets offers opportunities to induce distinct T responses. Here we report on the generation and use nanobodies (Nbs) target lentivectors specifically human lymph node-resident myeloid dendritic cells, demonstrating Nbs represent powerful tool redirect subsets.
To increase the safety and possibly efficacy of HIV-1 derived lentivectors (LVs) as an anti-cancer vaccine, we recently developed Nanobody (Nb) display technology to target LVs antigen presenting cells (APCs). In this study, extend these data with exclusive targeting conventional dendritic (DCs), which are believed be main cross-presenting APCs for induction a TH1-conducted antitumor immune response. The immunogenicity DC-subtype targeted was compared that broad tropism, general APC-targeted...